Boston Scientific Accrued Rebates, Current increased by 5.8% to $606.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 31.7%, from $460.00M to $606.00M. Over 4 years (FY 2020 to FY 2024), Accrued Rebates, Current shows an upward trend with a 10.5% CAGR.
other_accrued_rebates_current| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $354.00M | $351.00M | $350.00M | $329.00M | $335.00M | $341.00M | $352.00M | $347.00M | $363.00M | $369.00M | $389.00M | $384.00M | $412.00M | $460.00M | $494.00M | $519.00M | $573.00M | $606.00M |
| QoQ Change | — | -0.8% | -0.3% | -6.0% | +1.8% | +1.8% | +3.2% | -1.4% | +4.6% | +1.7% | +5.4% | -1.3% | +7.3% | +11.7% | +7.4% | +5.1% | +10.4% | +5.8% |
| YoY Change | — | — | — | — | -5.4% | -2.8% | +0.6% | +5.5% | +8.4% | +8.2% | +10.5% | +10.7% | +13.5% | +24.7% | +27.0% | +35.2% | +39.1% | +31.7% |